

Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030

<https://marketpublishers.com/r/OD785B1CBC26EN.html>

Date: June 2025

Pages: 329

Price: US\$ 4,950.00 (Single User License)

ID: OD785B1CBC26EN

Abstracts

The ophthalmology drugs market is expected to grow from USD 19.52 billion in 2025 to USD 26.28 billion by 2030, registering a CAGR of 6.1% during the forecast period. The growth of the ophthalmology drugs market has primarily been driven by the increasing prevalence of age-related eye diseases and the availability of several key therapies that address these conditions. Additionally, a robust pipeline of new drugs across various treatment modalities contributes to this growth. Opportunities for geographic expansion in emerging economies, such as Asia Pacific, Latin America, the Middle East, and Africa, also support the market's development.

The monoclonal antibodies & fusion proteins segment is expected to grow at the highest CAGR during the study period.

Monoclonal antibodies (mAbs) & fusion proteins are anticipated to experience the highest growth rate due to unmet needs in treating retinal diseases, advancements in drug delivery, and recent product approvals. The introduction of biosimilars and upcoming products, such as KSI-301, is expected to enhance competition and reduce costs. Key players in this market, including Regeneron and Roche, are vital for growth, while factors like payor acceptance and technological innovations significantly influence market dynamics.

In addition, emerging markets are increasingly adopting these treatments, benefiting from better access and more affordable pricing, particularly with biosimilars. Less

frequent dosing further enhances the cost-effectiveness of these therapies. Innovations such as sustained-release implants and gene therapies are also contributing to growth in this sector. Overall, biosimilars are expanding supply and increasing treatment volume.

The US is expected to grow at the highest CAGR in the global ophthalmology drugs market from 2025 to 2030.

The US is expected to experience the highest CAGR in the global ophthalmology drugs market between 2025 and 2035. This rapid growth is primarily driven by an aging population and the high prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME). Additionally, there are significant unmet medical needs, recent drug approvals like Syfovre and Izervay, and a promising pipeline for gene and cell therapies. The US also benefits from a strong research and development ecosystem, efficient FDA approval processes, and robust investment. Furthermore, a favorable reimbursement environment, Medicare coverage, and a willingness to adopt expensive therapies contribute significantly to this growth.

The primary interviews conducted for this report can be categorized as follows:

By Respondent: Supply Side (70%) and Demand Side (30%)

By Designation: Managers (45%), CXOs and Directors (30%), and Executives (25%)

By Region: North America (40%), Europe (25%), the Asia Pacific (25%), Latin America (5%), and the Middle East & Africa (5%)

List of Key Companies Profiled in the Report:

F. Hoffmann-La Roche Ltd. (Switzerland), Regeneron, Pharmaceuticals Inc. (US), Bayer AG (Germany), AbbVie (US), Novartis AG (Switzerland), Bausch + Lomb (US), Apellis Pharmaceuticals (US), Biogen (US), Astellas Pharma Inc. (US), and Formycon AG (Germany), among others.

Research Coverage:

This research report categorizes the ophthalmology drugs market by molecule

Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies...

(afibercept, faricimab, ranibizumab, and other molecules), modality (monoclonal antibodies & fusion proteins, small molecules, and other modalities), indication (age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and other indications), route of administration (intravitreal, topical, and other routes of administration), end user (hospitals, long-term care facilities, and specialty centers) and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).

The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the ophthalmology drugs market. A detailed analysis of the key industry players has been done to provide insights into their business overview, products, solutions, key strategies, collaborations, partnerships, and agreements. New approvals/launches, collaborations, acquisitions, and recent developments associated with the ophthalmology drugs market.

Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the ophthalmology drugs market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

Analysis of key drivers (aging population and growing prevalence of vision disorders, strong drug pipeline and growing innovation efforts, increasing investments and strategic collaborations, and improved reimbursement policies), restraints (off-label drug use for various indications), opportunities (shifting focus on new drug modalities, expansion into emerging markets, and high unmet needs), and challenges (frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment).

Product Development/Innovation: Detailed insights on upcoming products, research and development activities, and new product approvals/launches in the ophthalmology drugs market.

Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the ophthalmology drugs market.

Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the ophthalmology drugs market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
 - 1.3.2 INCLUSIONS & EXCLUSIONS
 - 1.3.3 YEARS CONSIDERED
 - 1.3.4 CURRENCY CONSIDERED
- 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH DATA
 - 2.1.1 SECONDARY DATA
 - 2.1.1.1 Objectives of secondary research
 - 2.1.1.2 Key data from secondary sources
 - 2.1.2 PRIMARY DATA
 - 2.1.2.1 Breakdown of primaries (supply- and demand-side participants)
 - 2.1.2.2 Key objectives of primary research
- 2.2 MARKET ESTIMATION METHODOLOGY
 - 2.2.1 GLOBAL MARKET ESTIMATION
 - 2.2.1.1 Product revenue analysis (bottom-up approach)
 - 2.2.1.2 Revenue share analysis of Regeneron Pharmaceuticals, Inc.
 - 2.2.1.3 MnM repository analysis
 - 2.2.1.4 Primary interviews
 - 2.2.2 INSIGHTS OF PRIMARY EXPERTS
 - 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (BOTTOM-UP APPROACH)
- 2.3 MARKET GROWTH RATE PROJECTIONS
- 2.4 DATA TRIANGULATION
- 2.5 STUDY ASSUMPTIONS
- 2.6 RESEARCH LIMITATIONS
- 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 OPHTHALMOLOGY DRUGS MARKET OVERVIEW
- 4.2 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE
- 4.3 OPHTHALMOLOGY DRUGS MARKET SHARE, BY END USER, 2024
- 4.4 OPHTHALMOLOGY DRUGS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

- 5.2.1.1 Aging population and growing prevalence of vision disorders
- 5.2.1.2 Strong drug pipeline and growing innovation efforts
- 5.2.1.3 Increasing investments and strategic collaborations
- 5.2.1.4 Improved reimbursement policies

5.2.2 RESTRAINTS

- 5.2.2.1 Off-label drug use for various indications

5.2.3 OPPORTUNITIES

- 5.2.3.1 Shifting focus on new drug modalities
- 5.2.3.2 Expansion into emerging markets
- 5.2.3.3 High unmet needs

5.2.4 CHALLENGES

- 5.2.4.1 Frequent and inconvenient intravitreal injections leading to patient non-adherence to treatment

5.3 TECHNOLOGY ANALYSIS

5.3.1 KEY TECHNOLOGIES

- 5.3.1.1 Hybridoma technology
- 5.3.1.2 Recombinant DNA technology
- 5.3.1.3 Antibody engineering
- 5.3.1.4 Gene therapy
- 5.3.1.5 Nanoformulations

5.3.2 ADJACENT TECHNOLOGIES

- 5.3.2.1 Optogenetic technology
- 5.3.2.2 Drug-release technologies
- 5.3.2.3 Ocular implant technologies

5.3.3 COMPLEMENTARY TECHNOLOGIES

- 5.3.3.1 3D printing and bioprinting
- 5.3.3.2 Ocular imaging technologies

5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.5 PRICING ANALYSIS

5.5.1 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024

5.5.2 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024

5.5.3 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024

5.6 VALUE CHAIN ANALYSIS

5.7 ECOSYSTEM ANALYSIS

5.7.1 OPHTHALMOLOGY DRUGS MARKET: ROLE OF RAW MATERIAL SUPPLIERS

5.7.2 OPHTHALMOLOGY DRUGS MARKET: ROLE OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES

5.7.3 OPHTHALMOLOGY DRUGS MARKET: ROLE OF END USERS

5.7.4 OPHTHALMOLOGY DRUGS MARKET: ROLE OF REGULATORY AUTHORITIES

5.8 PATENT ANALYSIS

5.9 REGULATORY ANALYSIS

5.9.1 REGULATORY LANDSCAPE

5.9.1.1 US

5.9.1.2 Europe

5.9.1.3 Emerging markets

5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.10 PORTER'S FIVE FORCES ANALYSIS

5.10.1 INTENSITY OF COMPETITIVE RIVALRY

5.10.2 BARGAINING POWER OF SUPPLIERS

5.10.3 BARGAINING POWER OF BUYERS

5.10.4 THREAT OF SUBSTITUTES

5.10.5 THREAT OF NEW ENTRANTS

5.11 KEY CONFERENCES & EVENTS, 2025–2026

5.12 REIMBURSEMENT SCENARIO

5.13 KEY STAKEHOLDERS & BUYING CRITERIA

5.13.1 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS

5.14 INVESTMENT & FUNDING SCENARIO

5.15 PIPELINE ANALYSIS

5.16 IMPACT OF ARTIFICIAL INTELLIGENCE ON OPHTHALMOLOGY DRUGS MARKET

5.16.1 CHALLENGES IN DRUG DISCOVERY

5.16.2 IMPACT OF AI ON DISCOVERY OF OPHTHALMOLOGY DRUGS

5.17 IMPACT OF 2025 US TARIFFS ON OPHTHALMOLOGY DRUGS MARKET

5.17.1 KEY TARIFF RATES

5.17.2 PRICE IMPACT ANALYSIS

5.17.3 KEY IMPACT ON VARIOUS REGIONS

5.17.3.1 US

5.17.3.2 Europe

5.17.3.3 APAC

5.17.4 MANUFACTURING INDUSTRY IMPACT

5.17.4.1 Ophthalmology drug manufacturers

6 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE

6.1 INTRODUCTION

6.2 AFLIBERCEPT

6.2.1 HIGH EFFICIENCY OF AFLIBERCEPT IN TREATING RETINAL DISEASES TO DRIVE MARKET GROWTH

6.3 FARICIMAB

6.3.1 GROWING ADOPTION AND POSITIVE OUTCOMES OF STUDIES TO SUPPORT MARKET GROWTH

6.4 RANIBIZUMAB

6.4.1 CLINICAL EFFICACY OF RANIBIZUMAB TO DRIVE ADOPTION

6.5 OTHER MOLECULES

7 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY

7.1 INTRODUCTION

7.2 MONOCLONAL ANTIBODIES & FUSION PROTEINS

7.2.1 GROWING FOCUS ON DEVELOPING NEW MABS TO DRIVE MARKET

7.3 SMALL MOLECULES

7.3.1 INCREASING INVESTMENTS AND RESEARCH TO DRIVE MARKET

7.4 OTHER MODALITIES

8 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION

8.1 INTRODUCTION

8.2 AGE-RELATED MACULAR DEGENERATION

8.2.1 WET AGE-RELATED MACULAR DEGENERATION

8.2.1.1 Increasing demand for effective therapies to drive market

8.2.2 DRY AGE-RELATED MACULAR DEGENERATION

8.2.2.1 Large market opportunity for innovation to drive growth

8.3 DIABETIC RETINOPATHY (DR)

8.3.1 FEWER APPROVED DRUGS TO PRESENT MARKET OPPORTUNITIES

8.4 DIABETIC MACULAR EDEMA (DME)

8.4.1 GROWING ADOPTION OF APPROVED ANTI-VEGF DRUGS FOR DME TO DRIVE MARKET

8.5 OTHER INDICATIONS

9 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION

9.1 INTRODUCTION

9.2 INTRAVITREAL

9.2.1 HIGH EFFICACY OF INTRAVITREAL INJECTIONS IN TREATMENT OF MAJOR RETINAL DISEASES TO DRIVE MARKET

9.3 TOPICAL

9.3.1 EASE OF USE TO DRIVE DEMAND FOR TOPICAL DRUGS

9.4 OTHER ROUTES OF ADMINISTRATION

10 OPHTHALMOLOGY DRUGS MARKET, BY END USER

10.1 INTRODUCTION

10.2 HOSPITALS

10.2.1 GROWING COLLABORATIONS BETWEEN HOSPITALS AND PHARMACEUTICAL COMPANIES TO ENCOURAGE GROWTH

10.3 LONG-TERM CARE FACILITIES

10.3.1 NEED FOR SUSTAINED MEDICAL SUPERVISION AND SUPPORT FOR CHRONIC CONDITIONS TO FUEL MARKET

10.4 SPECIALTY CENTERS

10.4.1 RISING INCLINATION TOWARD PERSONALIZED TREATMENT PLANS TO ACCELERATE GROWTH

11 OPHTHALMOLOGY DRUGS MARKET, BY REGION

11.1 INTRODUCTION

11.2 NORTH AMERICA

11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

11.2.2 US

11.2.2.1 Rising investments in healthcare research and development to support growth

11.2.3 CANADA

11.2.3.1 Rising government initiatives to support ophthalmology drugs research and increasing drug approvals to support growth

11.3 EUROPE

11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

11.3.2 GERMANY

11.3.2.1 Rising focus on clinical research to drive market

11.3.3 UK

11.3.3.1 Ongoing advancements in technology to drive market growth

11.3.4 FRANCE

11.3.4.1 Growing investments and government support to drive market growth

11.3.5 ITALY

11.3.5.1 Growing investments and research to support market

11.3.6 SPAIN

11.3.6.1 Growing geriatric population to drive market growth

11.3.7 REST OF EUROPE

11.4 ASIA PACIFIC

11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

11.4.2 CHINA

11.4.2.1 Large diabetic population to boost market

11.4.3 JAPAN

11.4.3.1 Growing aging population to intensify demand for effective treatments

11.4.4 INDIA

11.4.4.1 Increasing diabetic cases, government support, and growing availability of biosimilars to support market

11.4.5 AUSTRALIA

11.4.5.1 Strong biopharmaceutical sector to drive market growth

11.4.6 SOUTH KOREA

11.4.6.1 Strong R&D pipeline and increasing focus on research to support growth

11.4.7 REST OF ASIA PACIFIC

11.5 LATIN AMERICA

11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

11.5.2 BRAZIL

11.5.2.1 Significant rates of visual impairment in region to drive demand for advanced treatments

11.5.3 MEXICO

11.5.3.1 Growing research initiatives and innovations to support market growth

11.5.4 REST OF LATIN AMERICA

11.6 MIDDLE EAST

11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST

11.6.2 GCC COUNTRIES

11.6.2.1 Growing research initiatives and improving healthcare infrastructure to support growth

11.6.3 REST OF MIDDLE EAST

11.7 AFRICA

11.7.1 GROWING FOCUS ON HEALTHCARE TO DRIVE MARKET GROWTH

11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION

12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET

12.3 REVENUE ANALYSIS, 2022–2024

12.4 MARKET SHARE ANALYSIS, 2024

12.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS, 2024

12.5.1 STARS

12.5.2 EMERGING LEADERS

12.5.3 PERVASIVE PLAYERS

12.5.4 PARTICIPANTS

12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024

12.5.5.1 Company footprint

12.5.5.2 Region footprint

12.5.5.3 Molecule footprint

12.5.5.4 Modality footprint

12.5.5.5 Indication footprint

12.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024

12.6.1 PROGRESSIVE COMPANIES

12.6.2 RESPONSIVE COMPANIES

12.6.3 DYNAMIC COMPANIES

12.6.4 STARTING BLOCKS

12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024

12.6.5.1 Detailed list of key startups/SMEs

12.6.5.2 Competitive benchmarking of startups/SMEs

12.7 COMPANY VALUATION & FINANCIAL METRICS

12.7.1 VALUATION OF KEY PLAYERS

12.7.2 FINANCIAL METRICS OF KEY PLAYERS

12.8 BRAND/PRODUCT COMPARISON

12.9 COMPETITIVE SCENARIO

12.9.1 PRODUCT LAUNCHES & APPROVALS

12.9.2 DEALS

13 COMPANY PROFILES

13.1 KEY PLAYERS

13.1.1 REGENERON PHARMACEUTICALS INC.

13.1.1.1 Business overview

13.1.1.2 Products offered

13.1.1.3 Recent developments

13.1.1.3.1 Product approvals

13.1.1.4 MnM view

13.1.1.4.1 Right to win

13.1.1.4.2 Strategic choices

13.1.1.4.3 Weaknesses & competitive threats

13.1.2 F. HOFFMANN-LA ROCHE LTD.

13.1.2.1 Business overview

13.1.2.2 Products offered

13.1.2.3 Recent developments

13.1.2.3.1 Product launches & approvals

13.1.2.4 MnM view

13.1.2.4.1 Right to win

13.1.2.4.2 Strategic choices

13.1.2.4.3 Weaknesses & competitive threats

13.1.3 BAYER AG

13.1.3.1 Business overview

13.1.3.2 Products offered

13.1.3.3 Recent developments

13.1.3.3.1 Product approvals

13.1.3.4 MnM view

13.1.3.4.1 Right to win

13.1.3.4.2 Strategic choices

13.1.3.4.3 Weaknesses & competitive threats

13.1.4 NOVARTIS AG

13.1.4.1 Business overview

13.1.4.2 Products offered

13.1.4.3 Recent developments

- 13.1.4.3.1 Product approvals
- 13.1.4.3.2 Deals
- 13.1.4.4 MnM view
 - 13.1.4.4.1 Right to win
 - 13.1.4.4.2 Strategic choices
 - 13.1.4.4.3 Weaknesses & competitive threats
- 13.1.5 ABBVIE
 - 13.1.5.1 Business overview
 - 13.1.5.2 Products offered
- 13.1.6 APELLIS PHARMACEUTICALS
 - 13.1.6.1 Business overview
 - 13.1.6.2 Products offered
 - 13.1.6.3 Recent developments
 - 13.1.6.3.1 Product approvals
 - 13.1.6.3.2 Deals
- 13.1.7 BIOGEN
 - 13.1.7.1 Business overview
 - 13.1.7.2 Products offered
 - 13.1.7.3 Recent developments
 - 13.1.7.3.1 Product launches & approvals
- 13.1.8 BAUSCH + LOMB
 - 13.1.8.1 Business overview
 - 13.1.8.2 Products offered
 - 13.1.8.3 Recent developments
 - 13.1.8.3.1 Product launches & approvals
- 13.1.9 ASTELLAS PHARMA INC.
 - 13.1.9.1 Business overview
 - 13.1.9.2 Products offered
 - 13.1.9.3 Recent developments
 - 13.1.9.3.1 Product approvals
 - 13.1.9.3.2 Deals
- 13.1.10 FORMYCON AG
 - 13.1.10.1 Business overview
 - 13.1.10.2 Products offered
 - 13.1.10.3 Recent developments
 - 13.1.10.3.1 Product launches & approvals
 - 13.1.10.3.2 Deals
- 13.1.11 BIOCON
 - 13.1.11.1 Business overview

- 13.1.11.2 Products offered
- 13.1.11.3 Recent developments
 - 13.1.11.3.1 Product approvals
 - 13.1.11.3.2 Deals
- 13.1.12 SANDOZ GROUP AG
 - 13.1.12.1 Business overview
 - 13.1.12.2 Products offered
 - 13.1.12.3 Recent developments
 - 13.1.12.3.1 Product approvals
 - 13.1.12.3.2 Deals
- 13.1.13 SANTEN PHARMACEUTICAL CO., LTD.
 - 13.1.13.1 Business overview
 - 13.1.13.2 Products offered
 - 13.1.13.3 Recent developments
 - 13.1.13.3.1 Product launches
- 13.1.14 INNOVENT
 - 13.1.14.1 Business overview
 - 13.1.14.2 Products offered
 - 13.1.14.3 Recent developments
 - 13.1.14.3.1 Product approvals
- 13.1.15 OUTLOOK THERAPEUTICS, INC.
 - 13.1.15.1 Business overview
 - 13.1.15.2 Products offered
 - 13.1.15.3 Recent developments
 - 13.1.15.3.1 Product approvals
 - 13.1.15.3.2 Deals
- 13.1.16 TEVA PHARMACEUTICAL INDUSTRIES LTD.
 - 13.1.16.1 Business overview
 - 13.1.16.2 Products offered
 - 13.1.16.3 Recent developments
 - 13.1.16.3.1 Product approvals
 - 13.1.16.3.2 Deals
- 13.2 OTHER PLAYERS (PIPELINE COMPANIES)
 - 13.2.1 OCULAR THERAPEUTIX, INC.
 - 13.2.2 OPTHEA LIMITED
 - 13.2.3 KODIAK SCIENCES INC.
 - 13.2.4 EYEPOINT PHARMACEUTICALS, INC.
 - 13.2.5 ALVOTECH
 - 13.2.6 CLEARSIDE BIOMEDICAL

- 13.2.7 SHANGHAI HENLIUS BIOTECH, INC.
- 13.2.8 ADVERUM BIOTECHNOLOGIES, INC.
- 13.2.9 REMEGEN
- 13.2.10 SPARINGVISION

14 APPENDIX

- 14.1 DISCUSSION GUIDE
- 14.2 KNOWLEDGESTORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 14.3 CUSTOMIZATION OPTIONS
- 14.4 RELATED REPORTS
- 14.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS

TABLE 2 OPHTHALMOLOGY DRUGS MARKET: RISK ANALYSIS

TABLE 3 OPHTHALMOLOGY DRUGS MARKET: IMPACT ANALYSIS

TABLE 4 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY MOLECULE, 2024

TABLE 5 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY KEY PLAYER, 2024

TABLE 6 OPHTHALMOLOGY DRUGS MARKET: LIST OF RAW MATERIAL SUPPLIERS

TABLE 7 OPHTHALMOLOGY DRUGS MARKET: LIST OF PRODUCT PROVIDERS AND PHASE III PIPELINE PRODUCT COMPANIES

TABLE 8 OPHTHALMOLOGY DRUGS MARKET: LIST OF END USERS

TABLE 9 OPHTHALMOLOGY DRUGS MARKET: LIST OF REGULATORY AUTHORITIES

TABLE 10 OPHTHALMOLOGY DRUGS MARKET: INDICATIVE LIST OF PATENTS, 2024

TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 14 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 15 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 16 OPHTHALMOLOGY DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 17 OPHTHALMOLOGY DRUGS MARKET: LIST OF CONFERENCES & EVENTS

TABLE 18 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)

TABLE 19 BUYING CRITERIA FOR OPHTHALMOLOGY DRUGS, BY END USER

TABLE 20 OPHTHALMOLOGY DRUGS IN CLINICAL PIPELINE, PHASE III (AS OF APRIL 2025)

TABLE 21 US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 22 EXPORTS AND IMPORTS, BY REGION

TABLE 23 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 24 OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION)

TABLE 25 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 26 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 27 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 28 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 29 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AFLIBERCEPT, BY REGION, 2023–2030 (USD MILLION)

TABLE 30 OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION)

TABLE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 33 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 34 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 35 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR FARICIMAB, BY REGION, 2023–2030 (USD MILLION)

TABLE 36 OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION)

TABLE 37 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 38 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 39 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 40 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 41 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR RANIBIZUMAB, BY REGION, 2023–2030 (USD MILLION)

TABLE 42 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)

TABLE 43 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 44 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 45 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 46 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 47 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MOLECULES, BY REGION, 2023–2030 (USD MILLION)

TABLE 48 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 49 OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION)

TABLE 50 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 51 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 52 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 53 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 54 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR MONOCLONAL ANTIBODIES & FUSION PROTEINS, BY REGION, 2023–2030 (USD MILLION)

TABLE 55 OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)

TABLE 56 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 57 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 58 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 59 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SMALL

MOLECULES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 60 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SMALL MOLECULES, BY REGION, 2023–2030 (USD MILLION)

TABLE 61 OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 62 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 63 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 64 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 65 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 66 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER MODALITIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 67 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 68 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 69 OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 70 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 71 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 72 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 73 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 74 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 75 OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 76 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 77 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 78 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 79 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 80 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR WET AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 81 OPHTHALMOLOGY DRUGS MARKET FOR DRY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 82 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY REGION, 2023–2030 (USD MILLION)

TABLE 83 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 84 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC RETINOPATHY, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 85 OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION)

TABLE 86 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 87 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 88 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 89 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 90 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR DIABETIC MACULAR EDEMA, BY REGION, 2023–2030 (USD MILLION)

TABLE 91 OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 92 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 93 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 94 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 95 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 96 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER INDICATIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 97 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 98 OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF

ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 99 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 100 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 101 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 102 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 103 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR INTRAVITREAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 104 OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 105 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 106 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 107 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 108 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 109 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR TOPICAL ROUTE OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 110 OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 111 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 112 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 113 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 114 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 115 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2023–2030 (USD MILLION)

TABLE 116 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 117 OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)

TABLE 118 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 119 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 120 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 121 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 122 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)

TABLE 123 OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 124 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 125 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 126 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 127 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 128 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 129 OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 130 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 131 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 132 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 133 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 134 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR SPECIALTY CENTERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 135 OPHTHALMOLOGY DRUGS MARKET, BY REGION, 2023–2030 (USD

MILLION)

TABLE 136 NORTH AMERICA: MACROECONOMIC INDICATORSTABLE 137 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 138 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 139 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 140 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 141 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 142 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 143 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 144 US: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 145 US: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 146 US: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 147 US: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 148 US: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 149 US: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 150 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 151 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 152 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 153 CANADA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 154 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 155 CANADA: OPHTHALMOLOGY DRUGS MARKET, BY END USER,

2023–2030 (USD MILLION)

TABLE 156 EUROPE: MACROECONOMIC INDICATORS

TABLE 157 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 158 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 159 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 160 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 161 EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 162 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 163 EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 164 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 165 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 166 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 167 GERMANY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 168 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 169 GERMANY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 170 UK: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 171 UK: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 172 UK: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 173 UK: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 174 UK: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 175 UK: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030

(USD MILLION)

TABLE 176 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 177 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 178 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 179 FRANCE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 180 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 181 FRANCE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 182 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 183 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 184 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 185 ITALY: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 186 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 187 ITALY: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 188 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 189 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 190 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 191 SPAIN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 192 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 193 SPAIN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 194 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 195 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 196 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 197 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 198 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 199 REST OF EUROPE: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 200 ASIA PACIFIC: MACROECONOMIC INDICATORS

TABLE 201 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 202 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 203 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 204 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 205 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 206 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 207 ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 208 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 209 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 210 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 211 CHINA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 212 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 213 CHINA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 214 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

- TABLE 215 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
- TABLE 216 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
- TABLE 217 JAPAN: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 218 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
- TABLE 219 JAPAN: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
- TABLE 220 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
- TABLE 221 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
- TABLE 222 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
- TABLE 223 INDIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 224 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
- TABLE 225 INDIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
- TABLE 226 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
- TABLE 227 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
- TABLE 228 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)
- TABLE 229 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 230 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)
- TABLE 231 AUSTRALIA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)
- TABLE 232 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)
- TABLE 233 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)
- TABLE 234 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,

2023–2030 (USD MILLION)

TABLE 235 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 236 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 237 SOUTH KOREA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 238 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 239 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 240 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 241 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 242 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 243 REST OF ASIA PACIFIC: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 244 LATIN AMERICA: MACROECONOMIC INDICATORS

TABLE 245 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 246 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 247 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 248 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 249 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 250 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 251 LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 252 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 253 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 254 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION,

2023–2030 (USD MILLION)

TABLE 255 BRAZIL: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 256 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 257 BRAZIL: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 258 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 259 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 260 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 261 MEXICO: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 262 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 263 MEXICO: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 264 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 265 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 266 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 267 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 268 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 269 REST OF LATIN AMERICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 270 MIDDLE EAST: MACROECONOMIC INDICATORS

TABLE 271 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 272 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 273 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 274 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-

RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 275 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 276 MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 277 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 278 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 279 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 280 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 281 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 282 GCC COUNTRIES: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 283 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 284 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 285 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 286 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 287 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 288 REST OF MIDDLE EAST: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 289 AFRICA: MACROECONOMIC INDICATORS

TABLE 290 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2023–2030 (USD MILLION)

TABLE 291 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2023–2030 (USD MILLION)

TABLE 292 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2023–2030 (USD MILLION)

TABLE 293 AFRICA: OPHTHALMOLOGY DRUGS MARKET FOR AGE-RELATED MACULAR DEGENERATION, BY TYPE, 2023–2030 (USD MILLION)

TABLE 294 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF

ADMINISTRATION, 2023–2030 (USD MILLION)

TABLE 295 AFRICA: OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 296 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN OPHTHALMOLOGY DRUGS MARKET

TABLE 297 OPHTHALMOLOGY DRUGS MARKET: DEGREE OF COMPETITION

TABLE 298 OPHTHALMOLOGY DRUGS MARKET: REGION FOOTPRINT

TABLE 299 OPHTHALMOLOGY DRUGS MARKET: MOLECULE FOOTPRINT

TABLE 300 OPHTHALMOLOGY DRUGS MARKET: MODALITY FOOTPRINT

TABLE 301 OPHTHALMOLOGY DRUGS MARKET: INDICATION FOOTPRINT

TABLE 302 OPHTHALMOLOGY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES

TABLE 303 OPHTHALMOLOGY DRUGS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS

TABLE 304 OPHTHALMOLOGY DRUGS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–MAY 2025

TABLE 305 OPHTHALMOLOGY DRUGS MARKET: DEALS, JANUARY 2022–MAY 2025

TABLE 306 REGENERON PHARMACEUTICALS INC.: COMPANY OVERVIEW

TABLE 307 REGENERON PHARMACEUTICALS INC.: PRODUCTS OFFERED

TABLE 308 REGENERON PHARMACEUTICALS INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 309 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW

TABLE 310 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED

TABLE 311 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025

TABLE 312 BAYER AG: COMPANY OVERVIEW

TABLE 313 BAYER AG: PRODUCTS OFFERED

TABLE 314 BAYER AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 315 NOVARTIS AG: COMPANY OVERVIEW

TABLE 316 NOVARTIS AG: PRODUCTS OFFERED

TABLE 317 NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 318 NOVARTIS AG: DEALS, JANUARY 2021–MAY 2025

TABLE 319 ABBVIE: COMPANY OVERVIEW

TABLE 320 ABBVIE: PRODUCTS OFFERED

TABLE 321 APELLIS PHARMACEUTICALS: COMPANY OVERVIEW

TABLE 322 APELLIS PHARMACEUTICALS: PRODUCTS OFFERED

TABLE 323 APELLIS PHARMACEUTICALS: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 324 APELLIS PHARMACEUTICALS: DEALS, JANUARY 2021–MAY 2025

TABLE 325 BIOGEN: COMPANY OVERVIEW

TABLE 326 BIOGEN: PRODUCTS OFFERED

TABLE 327 BIOGEN: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025

TABLE 328 BAUSCH + LOMB: COMPANY OVERVIEW

TABLE 329 BAUSCH + LOMB: PRODUCTS OFFERED

TABLE 330 BAUSCH + LOMB: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025

TABLE 331 ASTELLAS PHARMA INC.: COMPANY OVERVIEW

TABLE 332 ASTELLAS PHARMA INC.: PRODUCTS OFFERED

TABLE 333 ASTELLAS PHARMA INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 334 ASTELLAS PHARMA INC.: DEALS, JANUARY 2021–JULY 2024

TABLE 335 FORMYCON AG: COMPANY OVERVIEW

TABLE 336 FORMYCON AG: PRODUCTS OFFERED

TABLE 337 FORMYCON AG: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025

TABLE 338 FORMYCON AG: DEALS, JANUARY 2021–MAY 2025

TABLE 339 BIOCON: COMPANY OVERVIEW

TABLE 340 BIOCON: PRODUCTS OFFERED

TABLE 341 BIOCON: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 342 BIOCON: DEALS, JANUARY 2021–MAY 2025

TABLE 343 SANDOZ GROUP AG: COMPANY OVERVIEW

TABLE 344 SANDOZ GROUP AG: PRODUCTS OFFERED

TABLE 345 SANDOZ GROUP AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 346 SANDOZ GROUP AG: DEALS, JANUARY 2021–JULY 2024

TABLE 347 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW

TABLE 348 SANTEN PHARMACEUTICALS CO., LTD.: PRODUCTS OFFERED

TABLE 349 SANTEN PHARMACEUTICAL CO., LTD: PRODUCT LAUNCHES, JANUARY 2021–MAY 2025

TABLE 350 INNOVENT: COMPANY OVERVIEW

TABLE 351 INNOVENT: PRODUCTS OFFERED

TABLE 352 INNOVENT: PRODUCT APPROVALS, JANUARY 2021–MAY 2025

TABLE 353 OUTLOOK THERAPEUTICS, INC.: COMPANY OVERVIEW

TABLE 354 OUTLOOK THERAPEUTICS, INC.: PRODUCTS OFFERED

TABLE 355 OUTLOOK THERAPEUTICS, INC.: PRODUCT APPROVALS, JANUARY 2022–MAY 2025

TABLE 356 OUTLOOK THERAPEUTICS, INC.: DEALS, JANUARY 2022–MAY 2025
TABLE 357 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
TABLE 358 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED
TABLE 359 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT APPROVALS,
JANUARY 2022–MAY 2025
TABLE 360 TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY
2022–MAY 2025
TABLE 361 OCULAR THERAPEUTIX, INC.: COMPANY OVERVIEW
TABLE 362 OPTHEA LIMITED: COMPANY OVERVIEW
TABLE 363 KODIAK SCIENCES INC.: COMPANY OVERVIEW
TABLE 364 EYEPOINT PHARMACEUTICALS, INC.: COMPANY OVERVIEW
TABLE 365 ALVOTECH: COMPANY OVERVIEW
TABLE 366 CLEARSIDE BIOMEDICAL: COMPANY OVERVIEW
TABLE 367 SHANGHAI HENLIUS BIOTECH, INC.: COMPANY OVERVIEW
TABLE 368 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW
TABLE 369 REMEGEN: COMPANY OVERVIEW
TABLE 370 SPARINGVISION: COMPANY OVERVIEW

List Of Figures

LIST OF FIGURES

FIGURE 1 OPHTHALMOLOGY DRUGS MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2 OPHTHALMOLOGY DRUGS MARKET: RESEARCH DESIGN

FIGURE 3 OPHTHALMOLOGY DRUGS MARKET: KEY DATA FROM SECONDARY SOURCES

FIGURE 4 OPHTHALMOLOGY DRUGS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS

FIGURE 5 OPHTHALMOLOGY DRUGS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024

FIGURE 6 PRODUCT REVENUE ANALYSIS-BASED ESTIMATION: BOTTOM-UP APPROACH (2024)

FIGURE 7 REVENUE SHARE ANALYSIS OF REGENERON PHARMACEUTICALS, INC. (2024)

FIGURE 8 OPHTHALMOLOGY DRUGS MARKET SIZE VALIDATION FROM PRIMARY SOURCES

FIGURE 9 OPHTHALMOLOGY DRUGS MARKET: BOTTOM-UP APPROACH

FIGURE 10 OPHTHALMOLOGY DRUGS MARKET: CAGR PROJECTIONS

FIGURE 11 OPHTHALMOLOGY DRUGS MARKET: DATA TRIANGULATION

FIGURE 12 OPHTHALMOLOGY DRUGS MARKET, BY MOLECULE, 2025 VS. 2030 (USD MILLION)

FIGURE 13 OPHTHALMOLOGY DRUGS MARKET, BY MODALITY, 2025 VS. 2030 (USD MILLION)

FIGURE 14 OPHTHALMOLOGY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2030 (USD MILLION)

FIGURE 15 OPHTHALMOLOGY DRUGS MARKET, BY INDICATION, 2025 VS. 2030 (USD MILLION)

FIGURE 16 OPHTHALMOLOGY DRUGS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 17 GEOGRAPHIC ANALYSIS: OPHTHALMOLOGY DRUGS MARKET

FIGURE 18 GROWING PREVALENCE OF RETINAL DISEASES AND INCREASING R&D INVESTMENTS TO DRIVE MARKET GROWTH

FIGURE 19 AFLIBERCEPT ACCOUNTED FOR LARGEST SHARE OF OPHTHALMOLOGY DRUGS MARKET IN NORTH AMERICA IN 2024

FIGURE 20 HOSPITALS TO DOMINATE MARKET DURING FORECAST PERIOD

FIGURE 21 NORTH AMERICA LIKELY TO BE FASTEST-GROWING MARKET IN

GLOBAL OPHTHALMOLOGY DRUGS MARKET DURING FORECAST PERIOD
FIGURE 22 OPHTHALMOLOGY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 23 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
FIGURE 24 INDICATIVE PRICING OF OPHTHALMOLOGY DRUGS, BY COUNTRY, 2024
FIGURE 25 OPHTHALMOLOGY DRUGS MARKET: VALUE CHAIN ANALYSIS
FIGURE 26 OPHTHALMOLOGY DRUGS MARKET: ECOSYSTEM ANALYSIS
FIGURE 27 OPHTHALMOLOGY DRUGS MARKET: PATENT PUBLICATION TRENDS, JURISDICTION, AND TOP APPLICANT ANALYSIS (JANUARY 2014–DECEMBER 2024)
FIGURE 28 OPHTHALMOLOGY DRUGS MARKET: PORTER'S FIVE FORCES ANALYSIS
FIGURE 29 KEY STAKEHOLDERS IN BUYING PROCESS OF OPHTHALMOLOGY DRUGS, BY MODALITY
FIGURE 30 KEY BUYING CRITERIA FOR END USERS
FIGURE 31 NORTH AMERICA: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
FIGURE 32 EUROPE: OPHTHALMOLOGY DRUGS MARKET SNAPSHOT
FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2022–2024 (USD MILLION)
FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2024
FIGURE 35 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 36 OPHTHALMOLOGY DRUGS MARKET: COMPANY FOOTPRINT
FIGURE 37 OPHTHALMOLOGY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 38 EV/EBITDA OF KEY PLAYERS
FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY PLAYERS
FIGURE 40 OPHTHALMOLOGY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 41 REGENERON PHARMACEUTICALS INC.: COMPANY SNAPSHOT (2024)
FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
FIGURE 43 BAYER AG: COMPANY SNAPSHOT (2024)
FIGURE 44 NOVARTIS AG: COMPANY SNAPSHOT (2024)
FIGURE 45 ABBVIE: COMPANY SNAPSHOT (2024)
FIGURE 46 APELLIS PHARMACEUTICALS: COMPANY SNAPSHOT (2024)
FIGURE 47 BIOGEN: COMPANY SNAPSHOT (2024)
FIGURE 48 BAUSCH + LOMB: COMPANY SNAPSHOT (2024)
FIGURE 49 ASTELLAS PHARMA INC.: COMPANY SNAPSHOT (2024)

FIGURE 50 FORMYCON AG: COMPANY SNAPSHOT (2024)

FIGURE 51 BIOCON: COMPANY SNAPSHOT (2024)

FIGURE 52 SANDOZ GROUP AG: COMPANY SNAPSHOT (2024)

FIGURE 53 SANTEN PHARMACEUTICAL CO., LTD.: COMPANY SNAPSHOT (2024)

FIGURE 54 INNOVENT: COMPANY SNAPSHOT (2024)

FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2024)

I would like to order

Product name: Ophthalmology Drugs Market by Molecule (Faricimab, Aflibercept, Ranibizumab), Modality (Monoclonal Antibodies & Fusion Proteins), RoA (Intravitreal, Topical), Indication (AMD, Diabetic Retinopathy (DR), DME), End User - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/OD785B1CBC26EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OD785B1CBC26EN.html>